GPT and congenital muscular dystrophy due to LMNA mutation: Despite the limited data on liver function outcomes, the results of this review provided early indication of the promising potential of MED-based interventions, including LCMD and LFMD, to improve hepatic outcomes by decreasing liver enzymes (e.g., AST, ALT), as well as certain biomarkers associated with MASLD severity (e.g., FIB-4, LSM, and IHL).